| Literature DB >> 35117349 |
Yan Chen1, Yingfeng Lin1, Zhaolei Cui1.
Abstract
BACKGROUND: Breast cancer is a common malignant tumor with increasing incidence worldwide. This study aimed to investigate the molecular mechanisms of the adriamycin (ADR) resistance in breast cancer.Entities:
Keywords: Breast cancer; adriamycin resistance; microarray data analysis
Year: 2020 PMID: 35117349 PMCID: PMC8797850 DOI: 10.21037/tcr-19-2145
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
The 5 up-regulated or down-regulated genes that were mostly enriched
| Expression | Genes | Adjust P value | LogFC |
|---|---|---|---|
| Up-regulation |
| 1.02E−4 | 9.9795696 |
|
| 1.02E−4 | 9.2300751 | |
|
| 1.02E−4 | 9.6770347 | |
|
| 1.02E−4 | 11.1822447 | |
|
| 1.02E−4 | 8.9519095 | |
| Down-regulation |
| 1.02E−4 | −10.4814297 |
|
| 1.02E−4 | −9.3188679 | |
|
| 1.2E−4 | −8.6980133 | |
|
| 1.48E−4 | −6.064777 | |
|
| 1.48E−4 | −8.8321929 |
FC, fold change.
The biological processes with enriched up-regulated or down-regulated genes
| Expression | Term | Count | P value | Benjamin |
|---|---|---|---|---|
| Up-regulation | Extracellular matrix organization | 24 | 6.9E−8 | 1.8E−4 |
| Positive regulation of transcription from RNA polymerase II promoter | 57 | 1.4E−5 | 1.8E−2 | |
| Lung development | 12 | 2.6E−5 | 2.2E−2 | |
| Positive regulation of gene expression | 22 | 9.9E−5 | 6.2E−2 | |
| Axon guidance | 15 | 5.5E−4 | 2.1E−1 | |
| Down-regulation | Homophilic cell adhesion via plasma membrane adhesion molecules | 15 | 2.9E−6 | 5.8E−3 |
| Positive regulation of transcription from RNA polymerase II promoter | 36 | 4.8E−4 | 1.5E−1 | |
| Signal transduction | 38 | 2.5E−3 | 4.3E−1 | |
| Cell-cell signaling | 13 | 4.6E−3 | 4.8E−1 | |
| Angiogenesis | 12 | 4.7E−3 | 4.7E−1 |
The cellular components with enriched up-regulated or down-regulated genes
| Expression | Term | Count | P value | Benjamin |
|---|---|---|---|---|
| Up-regulation | Plasma membrane | 179 | 3.2E−7 | 1.2E−4 |
| Extracellular space | 75 | 8.1E−7 | 1.5E−4 | |
| Extracellular region | 84 | 2.1E−6 | 2.5E−4 | |
| Basement membrane | 13 | 5.1E−6 | 4.6E−4 | |
| Cell surface | 36 | 3.3E−5 | 2.4E−3 | |
| Down-regulation | Extracellular exosome | 83 | 5.4E−5 | 1.4E−2 |
| Bicellular tight junction | 11 | 6.6E−5 | 8.7E−3 | |
| Plasma membrane | 109 | 2.3E−4 | 1.5E−2 | |
| Integral component plasma membrane | 44 | 2.0E−4 | 9.8E−3 | |
| Extracellular space | 41 | 4.2E−3 | 1.5E−1 |
The molecular functions with enriched up-regulated or down-regulated genes
| Expression | Term | Count | P value | Benjamin |
|---|---|---|---|---|
| Up-regulation | Heparin binding | 16 | 1.3E−4 | 8.6E−2 |
| Extracellular matrix structural constituent | 11 | 2.1E−4 | 6.7E−2 | |
| Signal transducer activity | 18 | 2.1E−4 | 4.5E−2 | |
| Transcription factor activity sequence-specific DNA binding | 51 | 2.2E−4 | 3.6E−2 | |
| RNA polymerase II core promoter proximal region sequence-specific binding | 18 | 1.1E−3 | 1.2E−1 | |
| Down-regulation | Calcium ion binding | 38 | 6.7E−8 | 3.4E−5 |
| RNA polymerase II core promoter proximal region sequence-specific binding | 20 | 2.0E−7 | 4.9E−5 | |
| RNA polymerase II core promoter proximal region sequence-specific binding | 16 | 4.3E−3 | 4.1E−1 | |
| Sequence-specific binding | 20 | 6.5E−3 | 4.8E−1 |
KEGG pathways with enriched differentially expressed genes (DEGs)
| Term | Count | P value | Benjamin |
|---|---|---|---|
| Pathways in cancer | 31 | 1.7E−6 | 3.8E−4 |
| Focal adhesion | 19 | 4.0E−5 | 4.6E−3 |
| Hematopoietic cell lineage | 11 | 2.5E−4 | 1.9E−2 |
| Amoebiasis | 11 | 1.2E−3 | 6.8E−2 |
| Calcium signaling pathway | 14 | 2.7E−3 | 1.2E−1 |
| Ras signaling pathway | 16 | 3.1E−3 | 1.1E−1 |
| PI3K AKT signaling pathway | 21 | 3.3E−3 | 1.0E−1 |
| Oxytocin signaling pathway | 12 | 5.2E−3 | 1.4E−1 |
| Cytokine-cytokine receptor interaction | 16 | 6.1E−3 | 1.3E−1 |
| Proteoglycans in cancer | 14 | 6.8E−3 | 1.3E−1 |
| MAPA signaling pathway | 16 | 8.7E−3 | 1.4E−1 |
KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 1The visualization of differentially expressed genes in the protein-protein interaction (PPI) network predicted by the Cytoscape software.
Degree assessment of hub genes
| Gene | Degree | MCC | MNC |
|---|---|---|---|
|
| 50 | 1,817 | 43 |
|
| 41 | 1,142 | 37 |
|
| 24 | 430 | 20 |
|
| 24 | 309 | 21 |
|
| 23 | 1,028 | 23 |
|
| 23 | 762 | 23 |
|
| 18 | 229 | 17 |
|
| 18 | 1,314 | 18 |
|
| 18 | 372 | 15 |
|
| 16 | 922 | 14 |
|
| 15 | 114 | 13 |
|
| 15 | 1,256 | 13 |
|
| 15 | 766 | 11 |
|
| 14 | 98 | 12 |
|
| 14 | 1,284 | 14 |
Figure 2The predicted 15 hub genes (adriamycin resistance) in the PPI network with high degree of association in breast cancer.
Figure 3Survival analysis of the identified genes, insulin like growth factor 1 receptor (IGF1R) and epithelial splicing regulatory protein 1 (ESRP1), in breast cancer cases. High expression level of IGF1R was associated with prolonged overall survival (A) and disease-free survival (B) in patients with breast cancer; elevated ESRP1 expression was associated with worse overall survival (C), but was not significant in disease free survival (D) in breast cancer cases.